Mode
Text Size
Log in / Sign up
N/A N=30 Randomized Triple-blind Treatment

Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus

Tinnitus

Enrolled (actual)
30
Serious AEs
10.0%
Results posted
Apr 2018
Primary outcome: Primary: Number of Participants With Serious Adverse Events — 1; 2 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
VNS Treatment (Device); VNS Control (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
MicroTransponder Inc.
Primary completion
May 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Serious Adverse Events
1; 2
SECONDARY
Number of Participants With Adverse Events
11; 9
SECONDARY
Change in Minimum Masking Level (MML) in Units of dB (Decibels)
3.5; -3.8
SECONDARY
Percent Change in Tinnitus Handicap Inventory (THI)
-17.7; -7.3
SECONDARY
Change in Tinnitus Handicap Questionnaire (THQ)
-2.5; -7.5

Summary

Assess the safety and efficacy of VNS paired with tones for tinnitus using a randomized, controlled, parallel study design.

Eligibility Criteria

Inclusion Criteria

  • 22 to 65 years of age
  • Have been diagnosed as suffering from sensorineural tinnitus and at least some tonal quality of the tinnitus
  • Unilateral or bilateral tinnitus
  • Have experienced tinnitus for at least one year and failed at least one tinnitus therapy (such as a counseling or sound therapy procedure. The diagnosis of tinnitus will include an audiological or medical diagnosis in their health records, as well as a patient affirmation of tinnitus greater than 12 months
  • MML >= 7 dB (decibel)
  • Have tinnitus score of 40 or greater on the Tinnitus Handicap Questionnaire; (THQ)
  • No tinnitus treatment for at least 4 weeks prior to study entry.
  • Willing and able to understand and comply with all study-related procedures during the course of the study

Exclusion Criteria

  • Acute or intermittent tinnitus
  • Severe hearing loss in any ear, as defined as more than an 80 dB HL (decibels hearing level) at frequencies from 250 Hz. to 8,000 Hz.
  • Meniere's disease, ear tumors, or evidence of active middle ear disease (such as fluid, infection, tumor, mass)
  • Any other implanted device such as a pacemaker or other neurostimulator; any other investigational device or drug
  • Pregnant or plan on becoming pregnant or breastfeeding during the study period
  • Currently require, or likely to require, MRI or diathermy during the study duration
  • History of adverse reactions to anesthetics (e.g., lidocaine) that in the Investigator's opinion make surgery too risky
  • Beck Depression Inventory (BDI) of 30 or greater
  • Any other form of tinnitus treatments (e.g. Herbal medication, acupuncture or chiropractic medicine) are not allowed during the study.
  • Any drug known to mimic, increase or decrease release or removal of a diffuse neuromodulator, such as norepinephrine, dopamine, serotonin, benzodiazepines, and acetylcholine is not allowed, as well as any psychoactive medications.
  • Significant cardiac history
  • Use of any medication known to cause or increase tinnitus, such as NSAIDS (ibuprofen, naproxen, nabumetone, etc.), aspirin and other salicylates, furosemide (Lasix) and other "loop" diuretics, "mycin" antibiotics such as vancomycin, quinine and related drugs, and chemotherapy agents such as cisplatin.
  • Involvement in litigation (e.g., worker's compensation claim and/or receiving disability benefits related to tinnitus and/or hearing loss).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01962558). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search